April 2024 | ISSUE #31

Patient and Family Advisory Council

Cuthbert Lab & Oncology Outcomes

Welcome

We are pleased to share that we have hired two new full-time staff members to join the Oncology Outcomes team: a Research Assistant and a Data Analyst. These positions will support and lead work on several meaningful projects and we are thrilled to see the team growing. We are also thrilled to share several recent publications from our trainees and junior staff:

Cuthbert Lab's master student Hannah has recently published her manuscript, <u>Improvement</u> <u>in patient-reported pain among patients with</u> <u>metastatic cancer and its association with opioid</u> <u>prescribing.</u>

O2 Research Assistant Chantelle published for the first time as the first author, with her paper <u>Next Generation Weight Loss Drugs for the</u> <u>Prevention of Cancer?</u>

O2 Research Assistant Abisola also published for the first time as the first author, with her manuscript <u>The projected health and economic</u> <u>impact of increased colorectal cancer screening</u> <u>participation among Canadians by income</u> <u>quintile</u>.



Research Highlights


Oncology Outcomes

Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.

STUDY PURPOSE

There is a lack of universally accepted standard of care treatments for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

A significant proportion of patients initially diagnosed with locoregionally advanced Oropharynx, HNSCC develop disease recurrence.



Assess treatment utilization and survival outcomes for R/M HNSCC in the real world setting.

CONCLUSIONS & FUTURE IMPACT

Overall survival remains similar across countries, despite differences in treatment patterns for R/M HNSCC.

> Prognosis remains poor. There are limited therapeutic options.

There is a need for newer, more efficacious treatments.

> Future research should explore the evolution of treatment patterns and survival outcomes in real-world practice after the recent clinical development of Immuno-oncology therapies for the treatment of R/M HNSCC.

Cuthbert Lab

Risk Stratification and Cancer Follow-Up: Towards More Personalized Post-Treatment Care in Canada

STUDY PURPOSE

Investigate the state of follow-up care for cancer survivors and the need for models of follow-up that are more personalized.



CONCLUSIONS & FUTURE IMPACT

Determining who is best served by which pathways and uneven coordination of care are a couple challenges that should be addressed to improve follow-up for cancer survivors.

Click here for full article.

Click here for full article.

Study Recruitment

We continue to actively recruit participants for several studies right now, including:

- Healthcare Provider and Patient Views on Prescribing Opioids for Cancer Patients. <u>Poster Link to Share</u>
- Patients Perspectives of Value Frameworks Used to Guide Oncology Treatment Decisions <u>Poster Link to Share</u>



Remote Assessment of Physical Fitness Measures: Reliability and Validity Study <u>Poster Link to Share</u>


If you think the studies might be relevant to your contacts, please feel free to share the website or poster links. For the additional details on each study click <u>here</u>.



The next newsletter will release in May 2024.

Previous issues of the PFAC newsletter have been posted online: <u>https://www.cuthbertlab.com/advisory-counci</u>l

Follow us on social media





SAVE THE DATE MAY 11, 2024 BUMRUN CALGARY

On May 11th the annual Bumrun will be held in Calgary. The Bumrun is a 5K walk/run founded by Dr. Ian Bookman to raise awareness for colorectal cancer and encourage early screenings. Since 2011, the Bumrun has raised over \$1M for colon cancer research, enhancing patient support programs for families living with colon cancer, and raising awareness of colon cancer screening and prevention.

